Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc.

GYRENYSE / NASDAQHealthcareSmall cap

$4.21-$0.31 (-6.9%)

Last close · Data as of Nov 20, 2026

Market cap
$600.6M
P/E
119.5x
EV / EBITDA
40.3x
Revenue
$116.6M
Net margin
4.3%
ROCE
7.8%

-43.8% over the last year

Gyre Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-31.8%
3M
-40.0%
6M
-30.3%
1Y
-43.8%
5Y
Hidden
  • This period includes a one-day price step on 13 Jan 2023 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.31 (-6.9%) from $4.52 to $4.21 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in GYRE, bought on each weekday since 2021.

News & filings

What Gyre Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was more than a hundred times interest costs.

Concerns (1)

  • The price is 37.4% below its 200-day average, and the 50-day average is below the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.

Read moreShow less

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Sector
Healthcare
Shares outstanding
83.8M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$600.6M
P/E
119.5x
P/B
5.7x
EV / EBITDA
40.3x
EV / Sales
4.8x
P/S
5.2x
52-week high
$8.76
52-week low
$4.01

Profitability

Operating margin
9.9%
Net margin
4.3%
EBITDA margin
12.0%
ROE
4.7%
ROCE
7.8%
ROIC
7.4%
ROA
3.0%
Asset turnover
0.70

Growth

Revenue
$116.6M
Revenue growth, 1Y
10.2%
Revenue CAGR, 3Y
4.5%
Net profit growth, 1Y
-58.4%
Free cash flow
-$913.0k

Solvency

Current ratio
5.60
Debt / Equity
0.01
Debt / Assets
0.01
CFO / Net profit
0.20
Cash / Market cap
6.2%

Where the revenue went

Of every $100 of FY2025 revenue, $4 was left as net income.

Gyre Therapeutics, Inc. income statement flow, FY2025
Gyre Therapeutics, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$5.4M
RevenueGross profit$111.2M
Gross profitResearch and development$13.7M
Gross profitSelling, general and administrative$86.0M
Gross profitOther operating expenses$0.00
Gross profitOperating income$11.5M
Operating incomePretax income$11.5M
Interest and other incomePretax income$2.9M
Pretax incomeTax and other$9.4M
Pretax incomeNet income$5.0M

Revenue and net profit

Revenue grew 10.2% in FY2025; net profit is the dashed line.

Gyre Therapeutics, Inc. revenue and net profit by fiscal year
Gyre Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$102.3M$2.3M
FY2023$113.5M-$92.9M
FY2024$105.8M$12.1M
FY2025$116.6M$5.0M

Cash flows

FY2025: $1.0M from operations, -$913.0k free after investment (dashed).

Gyre Therapeutics, Inc. operating and free cash flow by fiscal year
Gyre Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$10.7M$5.7M
FY2023$25.9M$17.3M
FY2024-$3.6M-$6.8M
FY2025$1.0M-$913.0k

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$116.6M+10.2%1Y
EBITDA
$14.0M-21.4%1Y
Net profit
$5.0M-58.4%1Y
Cash from operations
$1.0M
Free cash flow
-$913.0k
Revenue CAGR, 3Y
4.5%
Net profit CAGR, 3Y
29.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$116.6M$14.0M$5.0M-$913.0k4.7%+10.2%-58.4%

Monthly returns

Month-by-month returns of GYRE across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$166.1M
Liabilities$23.9M
Equity$142.3M
Paid-in capital$172.1M
Retained earnings-$68.4M
Minority interest$36.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; GYRE highlighted.

P/E against peers

GYRE trades at 119.5x earnings against a peer median of -2.5x.

  1. Gyre Therapeutics, Inc. (this company)119.5x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): First Tracks Biotherapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Gyre Therapeutics, Inc.GYREthis company$600.6M119.5x5.7x4.7%40.3x
First Tracks Biotherapeutics, Inc.TRAX$635.0M-3.9x1.6x-41.8%-3.0x
Prime Medicine, Inc.PRME$626.7M-3.1x5.2x-166.4%-3.4x
Beta Bionics, Inc.BBNX$619.0M-8.5x2.2x-25.5%-8.6x
Phreesia, Inc.PHR$599.0M259.7x1.8x0.7%21.3x
Ginkgo Bioworks Holdings, Inc.DNA$591.2M-1.9x1.2x-61.5%-3.4x
Bioventus Inc.BVS$589.4M25.9x3.2x12.3%8.4x
Altimmune, Inc.ALT$567.9M-6.4x2.5x-39.2%-6.4x
Tactile Systems Technology, Inc.TCMD$567.7M29.7x2.6x8.7%12.4x
Peer median—-2.5x2.3x-32.3%-3.2x

Year-to-date ROI

GYRE since 1 January, against earlier years.

Historical volatility

GYRE's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Gyre Therapeutics, Inc. operating margin by fiscal year
Gyre Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY20229.0%
FY202316.9%
FY202415.3%
FY20259.9%
LineFY2025
Cost of revenueCost Of Revenue$5.4M
Gross profitGross Profit$111.2M
Operating expensesOperating Expense$99.7M
Research and developmentResearch And Development$13.7M
Other operating expensesOther Operating Expenses—
Total expensesTotal Expenses$105.1M
Pretax incomePretax Income$14.4M

Learn while you research

Academy chapters picked for Gyre Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 119.5, learn when high multiples are justified.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →